Evidence Level
Research on Akkermansia muciniphila is still early but compelling. The landmark 2019 proof-of-concept RCT by Depommier et al. in Nature Medicine (n=32) found that pasteurized Akkermansia improved insulin sensitivity, reduced insulinemia by 28%, and decreased total cholesterol and relevant blood markers in overweight/obese volunteers over 3 months. Notably, pasteurized bacteria outperformed live bacteria, likely because the outer membrane protein Amuc_1100 — responsible for many of the metabolic benefits — is heat-stable and more bioavailable after pasteurization. Preclinical work in mice has consistently shown that Akkermansia supplementation prevents diet-induced obesity and improves gut barrier function. As of 2025, Akkermansia has received Novel Food approval from the European Food Safety Authority (EFSA), validating its safety profile for human consumption.